Survodutide 10mg / vial Ua Tau Zoo Tshaj Plaws Thiab Txhim Kho Metabolism

Survodutide 10mg / lub raj mis qhia

Pharmaceutical -qib dual receptor agonist peptide|Ua nyob rau hauv Suav teb, glucagon / GLP-1 receptor dual agonist 10mg / vial

Hom npeTom ntej: Survodutide (BI 456906)

Kev loj hlob codeib: 456906

Hom qauv: Acyl peptide raws li exendin-4 kev ua kom zoo dua qub

Hom phiaj: Glucagon receptor (GCGR) + glucagon-zoo li peptide-1 receptor (GLP-1R)

Purity: Ntau dua lossis sib npaug li 99.0% (HPLC kuaj pom)

Qhov tshwm sim: Dawb lyophilized hmoov

Cia: Khaws khov ntawm -20℃deb ntawm lub teeb; Tom qab thawing, refrigerate ntawm 2-8 degrees.

Core zoo thiab muaj nuj nqi

Survodutide (BI 456906) yog atshiab, ntev - ua yeeb yam dual agonist ntawm glucagon receptor (GCGR) thiab glucagon-zoo li peptide-1 receptor (GLP-1R), sawv cevib tug tom ntej - tiam kev taw qhia nyob rau hauv txoj kev loj hlob ntawm kev kho mob rau cov kab mob metabolic. Los ntawmib txhij ua kom ob lub ntsiab metabolic receptors, nws tau qhiamuaj peev xwm zoo dua piv rau ib leeg - receptor agonists hauv kev kho mob ntshav qab zib hom 2, rog rog, thiab tsis yog - kab mob cawv fatty siab / tsis yog- cawv steatohepatitis. Cov khoom no yogib qho tseem ceeb txiav- cov cuab yeej cuab tam rau kev kawm txog cov kab mob metabolic, kev txhim kho tshuaj, thiab tshuaj txhais lus.

✅ Dual mechanism ntawm kev ua:

GCGR agonist nyhuv:

Muaj zog nce kev siv hluav taws xob: Ua kom lub siab GCGR, ua kom nce basal metabolic tus nqi.

Txhim kho daim siab lipid metabolism: Txhawb nqa fatty acid oxidation hauv daim siab thiab txo cov roj deposition hauv daim siab.

Txhim kho cov ntshav lipid profile: txo qis triglycerides thiab tswj cov lipoprotein metabolism

GLP-1R agonist effect:

Kev tswj ntshav qab zib zoo: Glucose-nyob ntawm qhov tso tawm ntawm insulin thiab glucagon inhibition.

Central qab los noj mov: Ua rau ntawm qhov chaw pub mis hauv lub hypothalamus, ua rau muaj kev xav zoo ntawm kev puv.

Ncua lub plab khoob: Txo tus nqi ntawm kev nqus cov as-ham thiab ua kom lub siab puv.

Synergistic zoo:

Synergistic yuag poob los: Kev qab los noj mov + nce kev siv zog ua kom muaj zog ua kom poob phaus.

Kev txhim kho metabolic zoo: Tib lub hom phiaj rau ntau qhov kawg suav nrog qhov hnyav, ntshav qab zib, ntshav lipids, thiab daim siab rog.

Dosage optimization muaj peev xwm: Tej zaum yuav txo qhov kev pheej hmoo ntawm kev mob plab hnyuv cuam tshuam nrog siab - koob tshuaj GLP-1RAs

✅Qualityqhov zoo ntawm Suav manufacturers:

Advanced nthuav qhia platform: Kev sivSuav hamster zes qe menyuam (CHO) cellqhia qhov system kom paub tseeb tias muaj protein ntau folding thiab glycosylation.

Proprietary acylation technology: Mastering thev naus laus zis ntawmsite- qhia C18 diacid fatty acid saw hloov khokom ua tiav ntev - ua yeeb yamib zaug ib lub lim tiam.

Precision ntau lawm tswj:

Cov txheej txheem fermentation: Siab- kab lis kev cai ntawm tes ceev, cov khoom lag luam titer Ntau dua lossis sib npaug li 2g / L

Kev ua kom huv huv: Kev sib xyaw ua ke ntawm ntau- kauj ruam chromatography (kev sib raug zoo, kev sib pauv ion, hydrophobic, thiab molecular sieve) kom tshem tawm cov khoom tsis huv.

Kev Hloov Kho Validation: Mass Spectrometry Precisely Identifies Acylation Sites thiab Modification Efficiency

Kev tswj xyuas nruj nruj:

Purity: RP-HPLC purity Ntau dua lossis sib npaug li 99.0%, SEC-HPLC monomer cov ntsiab lus Ntau dua lossis sib npaug rau 98.5%

Kev ua si: Cell-raws li cAMP kev soj ntsuam xyuas cov haujlwm agonistic ntawm GCGR thiab GLP-1R (EC50 qhov tseem ceeb raws li qhov kev cia siab).

Qhov profile ntawm impurity: Txheeb xyuas cov khoom-txog impurities (xws li oxidation, deamidation, thiab disulfide daim ntawv cog lus tsis sib haum) thiab cov txheej txheem -txog impurities (lub party proteins, DNA), tag nrho cov uas yog nruj me ntsis tswj nyob rau hauv cov qauv.

Consistency: Muabcov ntaub ntawv pov thawj zoo xws lipeptide maps, pawg spectrometry, thiab ncig dichroism spectroscopypiv nrog tus thawj siv formulation.

Cov ntaub ntawv txhawb nqa tag nrho: MuabCov ntaub ntawv tshawb fawb zoo uas ua tau raws li cov kev xav tau ntawm kev tshawb fawb txog kev tshawb fawb thiab kev txhim kho thaum ntxov - theem.

✅ khoomNta:

Muaj zog dual agonist: Cov ntaub ntawv kho mob ua ntej lees paub tias nws qhov poob phaus thiab kev txhim kho metabolic muaj txiaj ntsig zoo dua rau ib leeg -cov phiaj xwm agonists.

Ultra-ntev- kav ntev: Optimized acylation hloov kho kev txhawb nqaib zaug -ib lub lim tiamsubcutaneous koob tshuaj, zoo heev txhim kho kev tshawb fawb yooj yim thiab ua raws.

Kev nyab xeeb yam ntxwv: Cov kev tshawb fawb preclinical tau pom tias nws muaj kev nyab xeeb zoo.

Daim ntawv qhia kev siv thiab cia

1. Kev kho dua tshiab thiab kev npaj:

Cov kuab tshuaj tshwj xeeb:

Yuav tsum tau siv cov tshuaj sterile reconstitution hnyav ntxiv(feem ntau yog dej rau kev txhaj tshuaj uas muaj qhov tsis zoo, pH kwv yees li 7.4).

Kev siv cov tshuaj physiological saline lossis dej tsis muaj menyuam rau kev txhaj tshuaj yog txwv tsis pub siv, raws li nws yuav cuam tshuam rau solubility thiab stability ntawm ntev - ua acylated peptide.

Tus txheej txheem npaj:

Noj 1.0 mL ntawm cov kuab tshuaj tshwj xeeb thiab maj mam txhaj nws raws phab ntsa sab hauv ntawm lub vial.

Maj mam tiglub vial horizontally nyob rau hauv xib-teg ntawm koj txhais tes rau tsawg kawg yog 1-2 feeb kom txog thaum lub ncuav mog qab zib khov-qhuav yog yaj tag, tsim ib tug ntshiab los yog me ntsis opalescent tov.Tsis txhob co los yog vortex vigorously.

10 mg/mlua tau.

Rau qis concentrations, dilute lub sij hawm thib ob nrogib qho kuab tshuaj tshwj xeeb los yog physiological saline uas muaj 0.1% tib neeg cov ntshav albumin.

Cov ntsiab lus tseem ceeb kom nco ntsoov:

Cov txheej txheem reconstitution yuav ua tau nyob rau hauv chav tsev kub.

Cov tshuaj reconstituted yuav tsum tau sivhauv 1 teevtiv thaiv kev sib sau los yog degradation.

Ua ntej kev tswj hwm, qhov kev daws teeb meem yuav tsum raug tshuaj xyuas kom pom tseeb tias tsis muajpom hais, fibers, los yog discoloration.

2. Cia tej yam kev mob:

Unreconstituted lyophilized hmoov:

Khaws khov ntawm -20℃± 5 degree, tiv thaiv los ntawm lub teeb nyob rau hauv thawj ntim.

Nyob rau hauv cov xwm txheej no, nws tuaj yeem nyob ruaj khovrau 24 lub hlis.

Rau ntev dua - lub sijhawm cia, khaws cia ntawm-80 degree.

Rov qab khov thiab thawing yog txwv tsis pub.

Reconstituted tshuaj daws:

Yog tias tsis siv tam sim ntawd, nws tuaj yeem ua taumuab tso rau hauv tub yees ntawm 2-8℃tsis pub ntau tshaj 24 teev.

Kev khov ntawm cov kev daws teeb meem rov qab tsis pom zoo.

Kev thauj mus los:

Ntev - yuav tsum muaj kev thauj mus losdej khov qhuav (-78 degree).

Lub ntsuas kub yuav tsum tau muab tso rau hauv lub ntim kom ntseeg tau tias muaj cov saw hlau txias thoob plaws hauv cov txheej txheem.

Kev xav txog kev ruaj ntseg:

Txias- cov hmoov qhuav yog qhov kub thiab txias; degradation yog nrawm ntawm qhov kub siab tshaj -10 degree.

Nws yog rhiab heev rau lub teeb thiab yuav tsum tau tuav thiab khaws cia deb ntawm lub teeb.

3. Kev tshawb fawb thiab kev npaj ua ntawv thov:

Preclinical tsiaj qauv:

Nyiam tus qauv:

Khoom noj khoom haus-induced rog (DIO) nas/rats: Tus qauv tseem ceeb rau kev ntsuas qhov poob phaus, noj zaub mov, thiab kev hloov pauv hauv lub cev muaj pes tsawg leeg (rog / nqaij sib piv).

Zucker Diabetic Obese (ZDF) naslos yogdb/db nas: siv los ntsuas qhov ua tau zoo ntawm cov tshuaj hypoglycemic thiab txhim kho cov tshuaj insulin.

Tsiaj qauv ntawm non{0}}alcoholic steatohepatitis (NASH)(xws li AMLN noj zaub mov-induced thiab STAM qauv): los soj ntsuam cov teebmeem ntawm kev txhim kho hepatic steatosis, o, ballooning degeneration, thiab fibrosis.

Dosage regimen:

Txoj kev pom zoo: txhaj tshuaj subcutaneous.

Kev tshawb nrhiav tshuaj(rau kev siv nkaus xwb, yuav tsum tau ua kom zoo raws li tus qauv tshwj xeeb):

Tsawg- pawg koob tshuaj: 0.03 - 0.1 mg/kg

Cov koob tshuaj nruab nrab: 0.3 - 1.0 mg/kg

Siab - pawg koob tshuaj: 3.0 - 10 mg/kg

Kev siv ntau zaus: Raws li nws qhov ntev - ua yeeb yam, nws tuaj yeem tsim los tswj hwm1-2 zaug hauv ib lub lis piam.

Kev kho mob thiab kev saib xyuas:

luv- lub sij hawm ua tau zoo: 4-8 lub lis piam.

Ntev - lub sij hawm ua tau zoo thiab cov txheej txheem: 12-26 lub lis piam.

Kev soj ntsuam cov ntsuas: lub cev qhov hnyav, noj zaub mov, ntshav qabzib (kev yoo mov, OGTT), ua tiav cov ntshav lipid profile, daim siab enzymes, cov ntsiab lus intrahepatic triglyceride (MRI lossis biochemical method), daim siab histology (NAFLD cov qhab nia, fibrosis qhab nia), thiab kev siv hluav taws xob (indirect calorimetry).

Mechanism ntawm kev kawm ua:

Receptor nyob thiab downstream signaling: Siv cov tshuaj tiv thaiv tshwj xeeb lossis kev sojntsuam, peb tshawb xyuas qhov muaj nyob ntawm GCGR thiab GLP-1R hauv cov ntaub so ntswg (xws li hypothalamus, daim siab, cov ntaub so ntswg dawb / xim av, thiab cov islets ntawm pancreatic) thiab ua kom cov dej ntws qis xws li cAMP thiab PKA.

Central mechanism: Siv cov tswv yim xws li kev xa tshuaj intraventricular, c-Fos immunostaining, thiab hauv vivo neuronal kaw, peb tau tshawb xyuas nws txoj cai ntawm lub chaw pub mis thiab lub zog tshuav nyiaj li cas.

Peripheral metabolism: Ua qhov hyperinsulin- orthoglucose clamp test kom raug ntsuas qhov tseeb ntawm cov tshuaj insulin rhiab heev thiab cov ntaub so ntswg- cov piam thaj tshwj xeeb pov tseg; Txheeb xyuas cov kab mob siab gluconeogenesis thiab lipid synthesis txoj hauv kev.

Ntau -omics tsom xam: Transscriptomic, proteomic, thiab metabolomic tsom xam tau ua nyob rau hauv cov ntaub so ntswg tseem ceeb xws li daim siab thiab adipose cov ntaub so ntswg kom systematically qhia lawv synergistic network.

4. Cov tswv yim tsim kev sim:

Tswj pab pawg teeb tsa:

Solvent tswj pawg

Tib - phiaj xwm tswj tau zoo (xws li GLP-1RA analogs)

Ib pab pawg kho mob ua ke yuav raug teeb tsa yog tias tsim nyog.

Kev tshawb nrhiav tshuaj: Nws raug pom zoo kom ua tiav koob tshuaj - teb kev sib raug zoo.

Vim li cas thiaj xaiv Suav - ua Survodutide?

Tshuabqhov zoo:

Nws muaj ob lub ntsiab technology platforms:complex recombinant protein qhiathiabntev - ua peptide hloov kho .

puv -chain R&D thiab muaj peev xwm tsim khoom,los ntawm kev tsim cov noob thiab kev tsim kho ntawm tes mus rau loj - nplai ntau lawm .

Cov txheej txheem zoo yog ua raws li cov qauv thoob ntiaj teb, thiab cov ntaub ntawv ua tiav thiab txhim khu kev qha.

Zoothiab Compliance Assurance:

Cov chaw tsim khoom ua tau raws li cov cai ntawm Tuam Tshoj NMPA cGMP.

Cov kev tshawb fawb zoo tau nyob hauv - qhov tob, qhov tsis huv ntawm qhov profile tau meej, thiab kev txheeb xyuas cov haujlwm tau zoo.

Nws muab cov ntaub ntawv qhia ntxaws ntxaws los txhawb siab - kev tshawb fawb zoo.

Muaj zogkev pabcuam thiab khoom siv:

cov kev tshawb fawb soj ntsuam xws li milligramsraugrams rau kev sim tshuaj preclinical,nyob ntawm seb koj xav tau kev tshawb fawb.

Pab pawg kws tshaj lij tuaj yeem muab kev pabcuam hauv - qhov tob xws likev sim tsim thiab kev txheeb xyuas cov ntaub ntawv.

Piv nrog rau cov khoom tuaj txawv teb chaws, nws muaj qhov tseem ceebqhov zoo ntawm tus nqi thiab lub voj voog xa khoom.

Tshawb nrhiav thiab siv cov lus qhia

Kev tshawb fawb txog cov txheej txheem ntawm cov kab mob metabolic:

Hla-Kev sib txuas lus thiab kev sib koom ua ke ntawm glucagon thiab GLP-1 txoj kev taw qhia

Central thiab peripheral kev koom ua ke mechanisms ntawm kev siv hluav taws xob thiab kev noj qab haus huv tswj

Regulatory network ntawm hepatic lipid metabolism thiab systemic zog homeostasis

Kev txhais cov tshuaj thiab kev txhim kho tshuaj tshiab:

Kev ntsuam xyuas tus nqi tshwj xeeb ntawm dual agonists hauv kev kho mob NASH / siab fibrosis

Tshawb nrhiav cov txiaj ntsig zoo rau cov kab mob plawv metabolic

Txhawm rau muab cov pov thawj preclinical rau optimizing dosing regimens (dosage, zaus).

Tshawb nrhiav Precision Medicine:

Tshawb nrhiav biomarkers los kwv yees cov lus teb kho mob

Txhawm rau tshawb nrhiav qhov sib txawv ntawm kev kho mob ntawm cov neeg mob uas muaj cov kab mob metabolic sib txawv (piv txwv li, feem ntau rog thiab feem ntau hepatic steatosis).

Preclinical kev tshawb fawb cov ntaub ntawv siv

Poob kev ua tau zoo: Hauv DIO qauv, nws qhov hnyav poob tau zoo dua li qhov sib npaug ntawm cov tshuaj GLP-1RA.

Kev txhim kho metabolic: Hauv cov qauv metabolic syndrome, nws tuaj yeem txhim kho tau zoontshav qabzib, ntshav lipids, siab enzymes thiab intrahepatic rog cov ntsiab lus ib txhij.

Synergistic nyhuv: Ib qho meejsynergistic nyhuv tau pom nyob rau hauv cov nqe lus ntawm lub zog noj thiab noj zaub mov inhibition.

Cov ntsiab lus

tom ntej no - lub hnub qub moleculehauv kev kho cov kab mob metabolic. Nwsdual GCGR / GLP-1R agonist mechanismmuab kev daws teeb meem tshiab rauntau zog thiab kev tswj cov metabolic. Tuam Tshoj cov tuam txhab, nrog lawv lub ntiaj teb- cov txheej txheem tsim khoom hauv chav kawm, kev tswj hwm kev tswj hwm zoo, thiab kev nkag siab tob txog kev txiav- ntug kev tshawb fawb, xyuas kom cov khoom muaj txiaj ntsig zoo - zoo, muaj zog heev, thiab ruaj khov heevkev tshawb fawb- cov ntaub ntawv qib rau cov koom tes tshawb fawb thoob ntiaj teb, ua rau lawv yog tus khub txhim khu kev qha rau kev tshawb nrhiav cov kev kho tshiab rau cov kab mob metabolic thiab ua rau muaj kev cuam tshuam txog kev tshawb fawb.

Xav taudab tsi, thov hu raupeb

Cim npe nrov: Tuam Tshoj survodutide 10mg / vial zoo heev yuag poob thiab txhim kho metabolism, Tuam Tshoj survodutide 10mg / vial zoo heev poob thiab txhim kho metabolism manufacturers, lwm tus neeg, Hoobkas